Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastroenteropancreatic Neuroendocrine Tumor Clear all
Active, not recruiting Phase 2 Interventional

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

NCT03891784
View directory record Official record
Conditions
Advanced Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Neoplasm, Midgut Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Refractory Digestive System Neuroendocrine Neoplasm
Interventions
Abemaciclib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

NCT02955069
View directory record Official record
Conditions
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
Interventions
PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 21, 2026, 5:56 PM EDT
Recruiting Phase 1 Interventional

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

NCT07150546
View directory record Official record
Conditions
Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions
Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Gallium Ga 68-DOTATATE, Positron Emission Tomography, Questionnaire Administration
Radiation · Drug · Procedure + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320
View directory record Official record
Conditions
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
433
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 290 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
Interventions
Bevacizumab, Temsirolimus
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
57
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 21, 2026, 5:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

NCT01841736
View directory record Official record
Conditions
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
412
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Recruiting Phase 4 Interventional

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

NCT06016855
View directory record Official record
Conditions
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2
Interventions
Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Active, not recruiting No phase listed Observational

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
LUTATHERA
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Portland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor
Interventions
Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jul 21, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

NCT00690430
View directory record Official record
Conditions
Symptomatic Refractory Resistant Carcinoid Disease
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Loma Linda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Jul 21, 2026, 5:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

NCT02948946
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
Interventions
NETest
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Jul 21, 2026, 5:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

NCT06427798
View directory record Official record
Conditions
Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
Interventions
68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Active, not recruiting Early Phase 1 Interventional

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

NCT04544098
View directory record Official record
Conditions
Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
Interventions
177Lu-DOTATATE
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Recruiting Phase 1 Interventional

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

NCT04609592
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, Gallium 68 Dotatate, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), PET/CT
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 21, 2026, 5:56 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

NCT04750954
View directory record Official record
Conditions
Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

NCT03220217
View directory record Official record
Conditions
Gastro-Enteropancreatic Neuroendocrine Tumor
Interventions
Satoreotide trizoxetan 5-20μg, Satoreotide trizoxetan 30-45μg
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Jul 21, 2026, 5:56 PM EDT
Completed No phase listed Observational

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

NCT06253897
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Jul 21, 2026, 5:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424
View directory record Official record
Conditions
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
673
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

NCT02250885
View directory record Official record
Conditions
Carcinoma, Neuroendocrine
Interventions
Selinexor
Drug
Lead sponsor
Gabrail Cancer Center Research
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 21, 2026, 5:56 PM EDT
Completed No phase listed Observational

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

NCT01423734
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
Interventions
magnetic resonance imaging (MRI)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Jul 21, 2026, 5:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889
View directory record Official record
Conditions
Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors
Interventions
Rovalpituzumab tesirine, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 21, 2026, 5:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
Interventions
Lutetium [177Lu] oxodotreotide/dotatate
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2034
U.S. locations
3
States / cities
Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 21, 2026, 5:56 PM EDT
Terminated Phase 2 Interventional Results available

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

NCT03042780
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
Interventions
FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jul 21, 2026, 5:56 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752
View directory record Official record
Conditions
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATE, Octreotide LAR
Radiation · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
19
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 21, 2026, 5:56 PM EDT